Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,770
Total Claims
$1.6M
Drug Cost
690
Beneficiaries
$2,331
Cost/Patient
Risk Score Breakdown 31/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-34%
Opioid rate vs peers
1.7% vs 2.6% avg
+118%
Cost per patient vs peers
$2,331 vs $1,068 avg
+58%
Brand preference vs peers
14.2% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
1.7%
Opioid Rate
387
Opioid Claims
$26K
Opioid Cost
18.1%
Long-Acting Rate
Brand vs Generic
Brand: 3,211 claims · $1.3M
Generic: 19,427 claims · $343K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Denosumab | 50 | $83K |
| Apixaban | 277 | $82K |
| Rivaroxaban | 316 | $76K |
| Fluticasone/Umeclidin/Vilanter | 83 | $69K |
| Dulaglutide | 65 | $66K |
| Sitagliptin Phosphate | 158 | $64K |
| Lipase/Protease/Amylase | 132 | $62K |
| Pimavanserin Tartrate | 52 | $60K |
| Empagliflozin | 78 | $55K |
| Dapagliflozin Propanediol | 98 | $50K |
| Semaglutide | 39 | $49K |
| Mirabegron | 109 | $35K |
| Fluticasone/Vilanterol | 74 | $33K |
| Liraglutide | 12 | $28K |
| Tirzepatide | 22 | $27K |
Prescribing Profile
Patient Profile
75
Avg Age
58%
Female
1.10
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About